Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs through its proprietary RaniPill® capsule platform. The RANI news page on Stock Titan aggregates company press releases, market announcements and regulatory updates so readers can follow how this oral biologics platform is progressing through preclinical and clinical development.
According to the company’s disclosures, recent news has highlighted pipeline milestones, such as preclinical data and the initiation of a Phase 1 clinical trial for RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist (PG-102) being developed for the treatment of obesity. Rani has also reported preclinical data on oral semaglutide (RT-116) and on oral delivery of a bispecific GLP-1/GLP-2 receptor agonist via RaniPill, with results described as comparable in bioavailability and weight loss to subcutaneous injections in animal models.
Investors and observers can use this news feed to track strategic collaborations and financings, including Rani’s Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. for an oral product combining RaniPill HC with a rare disease antibody, and its collaboration with ProGen Co., Ltd. for RT-114 in weight management. The company’s announcements also cover private placements, registered offerings, warrant transactions and related board changes tied to institutional investors.
In addition, Rani’s news includes quarterly financial results and corporate updates, where management discusses cash runway expectations, research and development spending and progress across its oral biologics pipeline. For anyone following RANI stock or the evolution of oral delivery technologies for biologics, this page offers a centralized view of company-generated news, from clinical trial plans to collaboration agreements and capital markets activity.
Rani Therapeutics announced positive topline results from Part 2 of its Phase 1 study for RT-102, an oral drug for osteoporosis. The study met all endpoints, with a 91% success rate in drug delivery via the RaniPill™ GO capsule, which was well tolerated by the participants, showing no serious adverse events. The data supports moving to a Phase 2 trial anticipated in H2 2023. Approximately 185 capsules have been administered in clinical studies, reinforcing the viability of the RaniPill™ platform for oral biologic delivery.
Rani Therapeutics reported its Q3 2022 financial results and key corporate updates on Nov. 10, 2022. The highlights include positive topline results from the Phase 1 study of RT-102, a proprietary PTH formulation, and the initiation of preclinical development for RT-111, a biosimilar targeting autoimmune conditions. Financially, Rani ended Q3 with cash reserves of $98.7 million. Although R&D expenses decreased to $9.1 million, the net loss reduced to $16.2 million from $28.7 million year-over-year. Upcoming milestones involve additional data from RT-102 and new Phase 1 studies in 2023.
Rani Therapeutics, a clinical stage biotherapeutics company, will present at the Stifel Healthcare Conference on November 15-16, 2022. CEO Talat Imran is scheduled to speak on November 16 at 9:45 AM EST. The company focuses on oral delivery of biologics through its innovative RaniPill capsule technology, aimed at replacing injections with oral dosing. Interested parties can access live webcasts from the Investor Relations section of their website, with replays available for 90 days post-presentation.
Rani Therapeutics announced the preclinical development of RT-111, an oral ustekinumab biosimilar targeting psoriatic arthritis, ulcerative colitis, Crohn's disease, and psoriasis. The product aims to simplify patient treatment by replacing injections with oral delivery.
Additionally, topline data for RT-102 is expected in Q4 2022, alongside the start of in vivo studies for the RaniPill HC. The company also plans to ramp up its pipeline with three new Phase 1 studies in 2023.
Rani Therapeutics Holdings (Nasdaq: RANI) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for September 12-14, 2022. CEO Talat Imran will deliver a presentation on September 12 at 8:30 AM EST. The conference will be accessible virtually and in-person, with a webcast available via the Investor Relations section of Rani's website. Rani Therapeutics focuses on innovative oral delivery systems for biologics, utilizing its patented RaniPill capsules to replace traditional injection methods.
Rani Therapeutics announced the termination of its previously announced underwritten public offering of Class A common stock, as management assessed the current market conditions as unfavorable. Consequently, no shares will be sold in this offering. The company asserted it has adequate capital to fund operations into mid-2024. The offering was to be conducted under an effective shelf registration statement. Forward-looking statements regarding cash reserves highlight potential risks and uncertainties affecting future results.
Rani Therapeutics Holdings has announced its intention to conduct an underwritten public offering of Class A common stock. The offering may include a 30-day option for underwriters to purchase up to 15% more shares. This action is contingent on market conditions and could affect the stock's performance. BofA Securities, Cantor, and UBS Investment Bank are leading the offering, which is being facilitated under a shelf registration statement effective as of August 10, 2022. The company emphasizes that no securities will be sold in jurisdictions where the offering would be unlawful.
Rani Therapeutics announced positive topline results from its Phase 1 trial of RT-102, a treatment for osteoporosis, demonstrating high oral bioavailability and successful drug delivery. The company completed a debt financing agreement of up to $45 million, ensuring operations are funded into mid-2024. Rani plans to initiate a third Phase 1 clinical trial and expects topline results from the repeat-dose portion of RT-102 by Q4 2022. As of June 30, 2022, cash and equivalents were $97.2 million, while R&D expenses rose significantly year-over-year to $9.5 million.
Rani Therapeutics announced positive topline results from its Phase 1 clinical study of RT-102, an oral capsule with human parathyroid hormone (PTH) analog for osteoporosis treatment. The study demonstrated that RT-102 was well-tolerated, with a 95% drug delivery success rate and a bioavailability of 300-400% greater than subcutaneous injections. The company aims to file an IND for Phase 2 trials by Q3 2023, building on the success of RT-101 and further validating the RaniPill platform.
Rani Therapeutics (RANI) reported its Q1 2022 financial results, highlighting the initiation of a Phase 1 trial for RT-102, aimed at treating osteoporosis. The company unveiled the RaniPill HC, which can deliver more than 20 mg of therapeutic payloads, enhancing its pipeline potential. Rani's cash position stood at $107.8 million, sufficient for operations through 2023. R&D expenses increased to $7.6 million, while general and administrative expenses rose to $6.2 million. The net loss for the quarter was $13.8 million, up from $5.6 million in Q1 2021.